CD274 and non-small cell lung carcinoma: A large Italian multicenter retrospective study including 1026 consecutive patients, evaluated the clinicopathologic correlates of Pembrolizumab effectiveness in previously untreated NSCLC patients with a PD-L1 expression ≥ 50% [84].